Search

Background: Considering the shared aetiology of Human Papillomavirus infections in oropharyngeal and cervical cancers and the possible role for sexual transmission, several key aspects of the relationship between cervical and oral infections merit investigation, including prevalence of concomitant oral HPV infection and type‐specific concordance with concurrent cervical infections. Methods: A cross‐section study was performed on women referred to colposcopy clinics with cytological abnormalities and a cervical HPV infection. An oral rinse sample was taken from the participants at their baseline visit for HPV testing, and a demographic and risk factor questionnaire was also administered. HPV DNA testing was carried out on the Cobas 4800 platform and extended genotyping was carried out with the INNO‐LiPA HPV Genotyping Extra II assay. HPV genotyping was also carried out on the concurrent cervical tissue samples on all women who had a positive oral HPV infection. Results: The prevalence of oral HPV infections was 10.0% (95%CI:5.9–13.7) in the study population. HPV18 was the most frequent genotype (7.0%). Concordant oral and cervical HPV infections were detected in 28.6% of women. Age (p = 0.005) and level of education (p = 0.02) were significantly associated with a prevalent oral HPV infection. Conclusion: Concomitant oral HPV infections were present in 10.0% of women referred to colposcopy with a pre‐existing cervical HPV infections and cytological abnormalities. Although mild type‐specific concordance was observed between oral and cervical HPV infections, findings suggest that infections at these sites may not be independent of each other. [ABSTRACT FROM AUTHOR]

The complex interplay between HIV and human papillomavirus and its link to cervical dysplasia is poorly understood. This is the first study to assess the prevalence of oncogenic human papillomavirus mRNA in HIV-positive women, its relationship to HIV and its potential use in the triage of cervical cancer screening in HIV-positive women. In this cross-sectional study, we included 321 HIV-positive women. In all, 28.7% had abnormal cervical cytology, 51.1% were human papillomavirus DNA-positive and 21.8% tested positive for human papillomavirus mRNA. Women with a CD4 count of <200 × 10(6)/L were more likely to test positive for human papillomavirus DNA and mRNA. Virally suppressed women were less likely to be human papillomavirus DNA-positive; however, the same did not hold true for human papillomavirus mRNA. We found the human papillomavirus mRNA screening to be more specific when screening for low-grade squamous intraepithelial lesion and high-grade squamous intraepithelial lesion than human papillomavirus DNA at 84.53% compared to 57.36%. However, the sensitivity was less at 51.59% versus 91.07% for human papillomavirus DNA. It may be possible in the future to use human papillomavirus mRNA/DNA testing within a triage algorithm for the screening and management of cervical cancer in the HIV-positive patient. [ABSTRACT FROM AUTHOR]

Highlights: [•] Full-Spectrum HPV test and HC2 had similarly high sensitivity for detection of HPV in women with CIN2+. [•] Molecular Beacon Real-Time HPV assay had the highest positive predictive value for CIN2+. [•] The most common HPV genotypes in this Irish colposcopy clinic were HPV16, 31, 33, 58, 18, 45, 59, 51, 56 and 39. [•] Multiple HPV infections were detected in 57.7% of colposcopy smears. [ABSTRACT FROM AUTHOR]